Here is a breakdown of the 10 priciest 340B medications:
- Keytruda (oncology): $6.91 billion in sales
- Biktarvy (HIV): $3.58 billion
- Opdivo (oncology): $1.95 billion
- Darzalex Faspro (oncology): $1.89 billion
- Ocrevus (oncology): $1.85 billion
- Trikafta (cystic fibrosis): $1.82 billion
- Humira (CF) Pen (immunology): $998.8 million
- Descovy (HIV): $969.5 million
- Entyvio (immunology): $949.7 million
- Durvalumab (oncology): $889.6 million
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.